Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00145236 |
Recruitment Status :
Completed
First Posted : September 5, 2005
Last Update Posted : September 14, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Drug: Nebivolol | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension. |
Study Start Date : | November 2001 |
Study Completion Date : | August 2003 |

- -Change in trough sitting diastolic blood pressure (DBP)at end of study compared to baseline
- -Change in sitting systolic blood pressure (SBP)
- -Change in supine and standing DBP and SBP
- -Response rate

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Black adults with an average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline.
Exclusion Criteria:
- Recent myocardial infarction or stroke
- Contraindication to beta-blocker therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00145236
United States, West Virginia | |
Mylan Pharmaceuticals Inc. | |
Morgantown, West Virginia, United States, 26505 |
Study Director: | Betty S. Riggs, MD, MBA | Mylan Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00145236 |
Other Study ID Numbers: |
NEB202 |
First Posted: | September 5, 2005 Key Record Dates |
Last Update Posted: | September 14, 2005 |
Last Verified: | September 2005 |
Nebivolol Beta-Blocker |
Hypertension Vascular Diseases Cardiovascular Diseases Nebivolol Antihypertensive Agents Vasodilator Agents Adrenergic beta-1 Receptor Agonists |
Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |